Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Targeting either GH or IGF-I during somatostatin analogue treatment in patients with acromegaly: a randomized multicentre study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Individual testosterone decline and future mortality risk in men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Characterisation and localisation of the endocannabinoid system components in the adult human testis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Possible link between FSH and RANKL release from adipocytes in men with impaired gonadal function including Klinefelter syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Characterization of Human Adrenal Steroidogenesis during Fetal Development

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Populations, decreasing fertility, and reproductive health

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Why do normal children have acromegalic levels of IGF-I during puberty?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

The acute metabolic actions of purified human growth hormone (GH) were first documented in adult hypopituitary patients more than 50 years ago, and placebo-controlled long-term GH trials in GH-deficient adults (GHDA) surfaced in 1989 with the availability of biosynthetic human GH. Untreated GHDA is associated with excess morbidity and mortality from cardiovascular disease and the phenotype includes fatigue, reduced aerobic exercise capacity, abdominal obesity, reduced lean body mass, osteopenia and elevated levels of circulating cardiovascular biomarkers. Several of these features reverse and normalize with GH replacement. It remains controversial whether quality of life, assessed by questionnaires, improves. The known side effects are fluid retention and insulin resistance, which are reversible and dose dependent. The dose requirement declines markedly with age and is higher in women. Continuation of GH replacement into adulthood in patients with childhood-onset disease is indicated, if the diagnosis is reconfirmed. GH treatment of frail elderly subjects without documented pituitary disease remains unwarranted. Observational data show that mortality in GH-replaced patients is reduced compared to untreated patients. Even though this reduced mortality could be due to selection bias, GH replacement in GHDA has proven beneficial and safe.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind179
Udgave nummer1
Sider (fra-til)R47-R56
ISSN0804-4643
DOI
StatusUdgivet - jul. 2018

ID: 56535544